Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The <scp>SEMALEAN</scp> study
The SEMALEAN study highlights the significant impact of Semaglutide 2.4 mg on weight loss, fat mass reduction, and muscle function improvement, with preserved lean mass and metabolic efficiency. These findings underscore the importance of a comprehensive approach to obesity management, addressing not only weight loss but also functional and metabolic adaptation.
Authors
- Thomas Demangeat
- Pierre Déchelotte (ORCID: https://orcid.org/0000-0001-5224-6166)
- Najate Achamrah (ORCID: https://orcid.org/0000-0003-4941-0564)
- V. Folope
- H. Van Elslande
- Hélène Lelandais
- Clément Rapp
- Alain Aubourg
- Moı̈se Coëffier (ORCID: https://orcid.org/0000-0002-7469-2682)
- Alexandra Aupetit (ORCID: https://orcid.org/0000-0002-4372-3116)
- Guillaume Colange
- S. Grigioni
- Pierre‐Emmanuel Cailleaux (ORCID: https://orcid.org/0000-0001-7814-7481)
- M. Godin
- André Petit
- S. Güney (ORCID: https://orcid.org/0000-0003-1393-5043)
- Luc Vignal (ORCID: https://orcid.org/0009-0004-4871-8262)
- Mathieu Alissou
- Julia Blanchemaison
Institutions
- Inserm (FR)
- Normandie Université (FR)
- Centre Hospitalier Universitaire de Rouen (FR)
- Université de Rouen Normandie (FR)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-10-09
- DOI
- https://doi.org/10.1111/dom.70141
- Citations
- 14
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 18.13